Immuron (IMRN) Retained Earnings (2016 - 2025)
Immuron (IMRN) posted quarterly Retained Earnings of -$824804.3 for Q3 2025, down 4.45% year-on-year from -$863193.9 in Q3 2024, and up 98.58% on a QoQ basis from -$58.2 million in Q2 2025.
Immuron (IMRN) Retained Earnings (2016 - 2025) Analysis & Trends
Immuron (IMRN) has reported Retained Earnings for 10 consecutive years, with -$824804.3 the latest figure, recorded in Q3 2025.
- Quarterly Retained Earnings fell 4.45% year-over-year to -$824804.3 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$824804.3 (down 4.45% YoY) and the FY2025 annual result came in at -$824804.3, down 4.45% from the prior year.
- Retained Earnings improved to -$824804.3 in Q3 2025 per IMRN's latest filing, from -$58.2 million in the prior quarter.
- Over the last five years, Retained Earnings for IMRN reached as high as $88.4 million in Q2 2023 and fell as low as -$58.2 million in Q2 2025.
- A 5-year average of -$26.7 million and a median of -$47.4 million in 2021 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2023 — Retained Earnings jumped 283.01% — and 2024, when it slumped 10759.15%.
- Year by year, Retained Earnings stood at -$46.6 million in 2021, then dropped by 3.78% to -$48.3 million in 2022, then soared by 98.92% to -$523514.3 in 2023, then plunged by 10759.15% to -$56.8 million in 2024, then surged by 98.55% to -$824804.3 in 2025.
- According to Business Quant data, Retained Earnings over the past three periods registered -$824804.3, -$58.2 million, and -$56.8 million for Q3 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Immuron | 270.20 Mn | 258.54 Mn | - | -824,804.27 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 2, 2025 | -824,804.27 |
| Jun 30, 2025 | -58.22 Mn |
| Dec 31, 2024 | -56.85 Mn |
| Sep 9, 2024 | -789,683.96 |
| Jun 30, 2024 | -55.77 Mn |
| Dec 31, 2023 | -523,514.31 |
| Sep 28, 2023 | -50.89 Mn |
| Aug 30, 2023 | -720,553.96 |
| Jun 30, 2023 | 88.44 Mn |
| Dec 31, 2022 | -48.32 Mn |
| Aug 31, 2022 | -48.32 Mn |
| Jun 30, 2022 | -48.32 Mn |
| Dec 31, 2021 | -46.56 Mn |
| Jun 30, 2021 | -46.56 Mn |
| Dec 31, 2020 | -632,871.95 |
| Sep 1, 2020 | -57.92 Mn |
| Jun 30, 2020 | -40.90 Mn |
| Dec 31, 2019 | -579,164.23 |
| Jun 30, 2019 | -56.86 Mn |
| Dec 31, 2018 | -52.54 Mn |